Bausch + Lomb (BLCO) ZACKS·2025-04-30 13:10Group 1 - Bausch + Lomb reported a quarterly loss of $0.07 per share, missing the Zacks Consensus Estimate of $0.03, and compared to earnings of $0.07 per share a year ago, representing an earnings surprise of -333.33% [1] - The company posted revenues of $1.14 billion for the quarter ended March 2025, missing the Zacks Consensus Estimate by 0.86%, and this is an increase from year-ago revenues of $1.1 billion [2] - Bausch + Lomb shares have declined approximately 24% since the beginning of the year, while the S&P 500 has decreased by 5.5% [3] Group 2 - The earnings outlook for Bausch + Lomb is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The trend for estimate revisions for Bausch + Lomb is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] - The current consensus EPS estimate for the upcoming quarter is $0.16 on revenues of $1.27 billion, and for the current fiscal year, it is $0.67 on revenues of $5 billion [7] Group 3 - The Medical Services industry, to which Bausch + Lomb belongs, is currently ranked in the top 29% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8]